In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Polymerase Chain Reaction (PCR) Systems are instruments used to perform nucleic acid amplification, typically in support of investigations concerning the diagnosis or prognosis of cancer or infectious disease. GlobalData uses proprietary data and analytics to provide a comprehensive report on the pcr systems devices market, including market shares of different players within Japan. Buy the latest report here.
Smarter leaders trust GlobalData
In 2022, GlobalData’s Market Model methodology determined that the leading player in the pcr systems market in Japan was F. Hoffmann-La Roche followed by Bio-Rad Laboratories, Thermo Fisher Scientific, bioMerieux, Qiagen, Abbott Laboratories, Siemens, Danaher, Becton Dickinson and Co, Hologic and Standard BioTools.
The Polymerase chain reaction (PCR) is a method used to amplify and analyze short DNA (or RNA) sequences in a sample with small quantities of RNA or DNA, through repeated heating and cooling of nucleic acids, combined with recombinant enzymes, to mimic the natural process used in cells to repair DNA. PCR amplifies the selected sequence of DNA segment producing millions of copies within a few hours. Quantitative PCR (qPCR) is a modification of the technique that allows measurement of the amplified RNA or DNA. The Polymerase Chain Reaction (PCR) Systems tracks the essential equipment only, and not accessories and/or additional costs associated with PCR System installation. It includes the sub-segments Semi Automated qPCR Systems, Automated qPCR Systems, and Digital PCR Systems.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the pcr systems devices market within Japan was expected to be over $100m in 2022.
For the latest complete market share analysis of pcr systems device market in Japan, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
